Biomea Fusion【BMEA】銘柄情報

Biomea Fusion Inc (BMEA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.23

( - )

買値

1.10

売値

1.53

出来高

460,237

1.2208 日の範囲 1.285

0.8719 52 週間の範囲 2.99

時価総額

88.928M

前日終値

1.23

始値

1.23

時刻

1.2597

最終取引時間

財務取引量

US$ 578,935

VWAP

1.2579

平均取引量 (3 か月)

US$ 1,511,288

発行済株式数

72,299,440

配当利回り

PER

-1.61

1 株当たり利益 (EPS)

-0.74

歳入

純利益

-44.95M

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical tria... Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

biomeafusion.com

本社

San Carlos, United States

設立

2026

Biomea Fusion Inc is listed in the Healthcare sector of the ナスダック市場 with ticker BMEA. The last closing price for Biomea Fusion was US$1.23. Over the last year, Biomea Fusion shares have traded in a share price range of US$ 0.8719 to US$ 2.99.

Biomea Fusion currently has 72,299,440 shares in issue. The market capitalisation of Biomea Fusion is US$88.93 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -1.61.

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat...

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for...

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the...

Form 8-K - Current report

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.02	1.65289256198	1.21	1.31	1.15	831212	1.19547074	CS
4	-0.21	-14.5833333333	1.44	1.48	1.1	1001040	1.2638067	CS
12	-0.1	-7.51879699248	1.33	2.237	1.1	1477048	1.58169254	CS
26	-0.1077	-8.05113254093	1.3377	2.237	1.03	1280149	1.45659309	CS
52	-0.59	-32.4175824176	1.82	2.99	0.8719	1380233	1.58261393	CS
156	-31.27	-96.2153846154	32.5	33	0.8719	1179661	6.0788855	CS
260	-16.51	-93.0665163472	17.74	43.69	0.8719	812464	8.16182472	CS